Corporate symposia
| Satellite symposium 1 Sponsored by Yuhan |
17:30~18:00 / Thursday 11 October Convention hall B Chairman: Sung Koo Kang |
|
|---|---|---|
|
SS1 Why should we consider SGLT-2i treatment for T2DM patients? | |
| Satellite symposium 2Sponsored by Chongkundang |
Thursday 11 October 17:30~18:00 / 222 Convention hall C Chairman: Min Young Chung |
|
|---|---|---|
|
SS2 What should be considered in choosing diabetic drug? : focused on synergistic effect of TZD and SGLTI | |
| Satellite symposium 3Sponsored by Takeda |
15:20~16:00 / Friday 12 October Convention hall A Chairman: Ho Young Son |
|
|---|---|---|
|
SS3 Targeting beta-cell function in T2DM: a critical factor for durability | |
| Satellite symposium 4Sponsored by Novonordisk |
15:20~16:00 / Friday 12 October Convention hall B Chairman: Sung Woo Park |
|
|---|---|---|
|
SS4 Exploring the mechanisms behind better PPG control with faster aspart | |
| Satellite symposium 5Sponsored by Lilly |
15:20~16:00 / Friday 12 October Convention hall C Chairman: Moon-Gi Choi |
|
|---|---|---|
|
SS5 Beyond basal insulin treatment: basal insulin combination with GLP-1RA | |
| Breakfast symposium 1Sponsored by MSD |
08:00~09:00 / Friday 12 October Grand Ballroom A Chairman: Jin Woo Kim |
|
|---|---|---|
|
BS1 Optimized treatment for type 2 DM patients-focusing new SGLT2i, ertugliflozin | |
| Breakfast symposium 2Sponsored by Novartis |
08:00~09:00 / Friday 12 October Grand Ballroom C Chairman: Hyoung Woo Lee |
|
|---|---|---|
|
BS2 Anti-diabetic agents with high potency and low risk of hypoglycemia: reducing glucose fluctuation | |
| Breakfast symposium 3Sponsored by Sanofi Aventis |
08:00~09:00 / Saturday 13 October Grand Ballroom A Chairman: Young-Kil Choi |
|
|---|---|---|
|
BS3 Glargine 300 “complementing randomized controlled trials with real-world evidence" | |
| Breakfast symposium 4Sponsored by JW Pharmaceutical |
08:00~09:00 / Saturday 13 October Grand Ballroom C Chairman: Yong Ki Kim |
|
|---|---|---|
|
BS4 The additional benefit of anagliptin beyond glycemic control | |
| Luncheon symposium 1Sponsored by Astrazeneca |
12:10~13:20 / Friday 12 October Convention hall A Chairman: Soon Jib Yoo |
|
|---|---|---|
|
LS1 The DECLARE-TIMI 58 design and patients baseline characteristics: compression to all other CVOTs with SGLT2-INH and its implication | |
| Luncheon symposium 2Sponsored by Dong-A ST |
12:10~13:20 / Friday 12 October Convention hall B Chairman: Dong-Seop Choi |
|
|---|---|---|
|
LS2 The newest ARB, edarbi for hypertensive patients with T2DM | |
| Luncheon symposium 3Sponsored by Ildong |
12:10~13:20 / Friday 12 October Convention hall C Chairman: Hyung Joon Yoo |
|
|---|---|---|
|
LS3 DPP4 inhibitor : beta cell protection and albuminuria improvement effect found from evidence | |
| Luncheon symposium 4Sponsored by Daewoong |
12:10~13:20 / Friday 12 October Emerald hall A Chairman: Kyo Il Suh |
|
|---|---|---|
|
LS4 Effect of dapagliflozin on vascular function in diabetes | |
| Luncheon symposium 5Sponsored by LG |
12:20~13:30 / Saturday 13 October Convention hall A Chairman: Hyun Chul Lee |
|
|---|---|---|
|
LS5 Review of clinical studies comparing DPP-4 inhibitors | |
| Luncheon symposium 6Sponsored by Handok |
12:20~13:30 / Saturday 13 October Convention hall B Chairman: Duk Kyu Kim |
|
|---|---|---|
|
LS6 The multiple benefits of ipragliflozin; ideal option for Asian T2DM patients | |
| Luncheon symposium 7Sponsored by Boehringer Ingelheim |
12:20~13:30 / Saturday 13 October Convention hall C Chairman: Young Seol Kim |
|
|---|---|---|
|
LS7 New drugs new opportunities for diabetes and its complications | |
